Stimulation of tumour necrosis factor-α production by recombinant human erythropoietin may contribute to failure of therapy

Scandinavian Journal of Urology and Nephrology

Volumn 34, Issue 2, 2000, Pages 131-135

  Takemasa, A ^a   Yorioka, N ^a   Ueda, C ^a   Amimoto, D ^a   Taniguchi, Y ^a   Yamakido, M ^a  

^a HIROSHIMA UNIV SCHOOL OF MEDICINE   (Japan)

Author keywords

Continuous ambulatory peritoneal dialysis; Erythropoietin; Renal anaemia; Tumour necrosis factor ; Unresponsiveness to erythropoietin therapy

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANEMIA; ARTICLE; CLINICAL ARTICLE; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CYTOKINE PRODUCTION; ERYTHROPOIESIS; FEMALE; HEMATOCRIT; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION TEST; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; SUPERNATANT; TREATMENT FAILURE;

ADULT; ANEMIA; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HUMANS; MALE; MIDDLE AGED; PERITONEAL DIALYSIS, CONTINUOUS AMBULATORY; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034520628     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655900750016760     Document Type: Article

References (28)

1. Effects of recombinant human tumor necrosis factor (rhTNF) on normal human and mouse hemopoietic progenitor cells
2. In vivo hematopoietic effects of tumor necrosis factor-α in normal and erythroleukemic mice: Characterization and therapeutic applications
3. Chronic exposure to tumor necrosis factor in vivo preferentially inhibits erythropoiesis in nude mice
4. Macrophage control of normal and leukemic erythropoiesis: Identification of the macrophage-derived erythroid suppressing activity as interleukin-1 and the mediator of its in vivo action as tumor necrosis factor
5. In vivo suppression of erythropoiesis by tumor necrosis factor-α (TNF-α): Reversal with exogenous erythropoietin (EPO)
6. Erythropoietin fails to reverse the anemia in mice continuously exposed to tumor necrosis factor-alpha in vivo
7. Anaemia in rheumatoid arthritis: Role of cytokines
8. Recombinant human erythropoietin increases interleukin-1β production in cultured peripheral blood mononuclear cells from patients resistant to recombinant human erythropoietin therapy
9. Stimulation of interleukin-1β production may be involved in unresponsiveness to erythropoietin therapy
10. Investigation of the influenza-like symptoms associated with recombinant human erythropoietin therapy
11. 3 regulate the response to human recombinant erythropoietin in uremia: In vitro and in vivo studies
12. The response to recombinant human erythropoietin in patients with the anemia of end-stage renal disease is correlated with serum carnitine levels
13. L-carnitine effects on anemia in hemodialyzed patients treated with erythropoietin
14. The intensity of hemodialysis and the response to erythropoietin in patients with end-sage renal disease
15. Influence of the treatment with recombinant human erythropoietin on plasma concentration of interleukin-1-alpha and tumour necrosis factor-alpha in hemodialyzed subjects
16. Effect of recombinant human erythropoietin on interleukin-1β and interleukin-6 in patients on maintenance hemodialysis
17. Inhibition by interleukin-1 of the action of erythropoietin on erythroid precursors and its possible role in the pathogenesis of hypoplastic anaemias
18. In vivo hematopoietic effects of recombinant interleukin-1α in mice: Stimulation of granulocytic, monocytic, megakaryocytic, and early erythroid progenitors, suppression of late-stage erythropoiesis, and reversal of erythroid suppression with erythropoietin
19. Suppression of normal human erythropoiesis by gamma interferon in vitro. Role of monocytes and T lymphocytes
20. Relationship between sugar chain structure and biological activity of recombinant human erythropoietin produced in Chinese hamster ovary cells
21. 125I-KRN5702 after a single intravenous dose in rats
22. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients
23. Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells
24. Acute effects of recombinant human erythropoietin on plasma levels of proendothelin-1 and endothelin-1 in haemodialysis patients
25. Recombinant human erythropoietin activates a broad spectrum of progenitor cells
26. Effect of recombinant human erythropoietin on human IgE production in vitro
27. Human recombinant erythropoietin directly stimulates B cell immunoglobulin production and proliferation in serum-free medium
28. Effect of recombinant human erythropoietin administration on immunological indices in patients undergoing chronic hemodialysis